149 related articles for article (PubMed ID: 31380858)
1. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
Du P; Guan Y; An Z; Li P; Liu L
Analyst; 2019 Sep; 144(18):5462-5471. PubMed ID: 31380858
[TBL] [Abstract][Full Text] [Related]
2. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Qiu X; Lin Q; Ning Z; Qian X; Li P; Ye L; Xie S
J Pharm Biomed Anal; 2019 Mar; 166():66-70. PubMed ID: 30612075
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats.
Li B; Wang J; Dou X; Zhang X; Xue X; Xu Q; Ran W; Xiong S
Comb Chem High Throughput Screen; 2021; 24(9):1410-1416. PubMed ID: 33155888
[TBL] [Abstract][Full Text] [Related]
4. A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline.
Sun S; Cheng D; Kong S; Li X; Li T; Yu Q; Wang L
Biomed Chromatogr; 2020 Jan; 34(1):e4703. PubMed ID: 31629393
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
Ezzeldin E; Iqbal M; Al-Salahi R; El-Nahhas T
J Pharm Biomed Anal; 2019 Mar; 166():244-251. PubMed ID: 30665192
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies.
Heudi O; Vogel D; Lau YY; Picard F; Kretz O
Anal Bioanal Chem; 2014 Nov; 406(28):7389-96. PubMed ID: 25258279
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Veeraraghavan S; Viswanadha S; Thappali S; Govindarajulu B; Vakkalanka S; Rangasamy M
J Pharm Biomed Anal; 2015 Mar; 107():151-8. PubMed ID: 25594893
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
10. A rapid and sensitive LC-MS/MS method for evaluation of the absolute oral bioavailability of a novel c-Met tyrosine kinase inhibitor QBH-196 in rats.
Zhang Q; Sun J; Lu T; Zhang J; Wu C; Li L; He Z; Zhao Y; Liu X
Biomed Chromatogr; 2015 Nov; 29(11):1650-6. PubMed ID: 25880630
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC-MS/MS in Human Plasma: Application in NSCLC Patients.
Liu Y; Lin Z; Luo W; Pei X; She Z; Sha Z; Guan Y; Ming D; Liang J
J Chromatogr Sci; 2024 Apr; 62(4):339-346. PubMed ID: 37070405
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies.
Maher HM; Alzoman NZ; Shehata SM
J Pharm Biomed Anal; 2016 May; 124():216-227. PubMed ID: 26966895
[TBL] [Abstract][Full Text] [Related]
13. Determination of fascaplysin in rat plasma with ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS): application to a pharmacokinetic study.
Hu Z; Zhang M; He M; Fang B; Bao X; Yan X; Liang H; Wang H
J Pharm Biomed Anal; 2019 Jul; 171():126-131. PubMed ID: 30986762
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study.
Ezzeldin E; Iqbal M; Herqash RN; ElNahhas T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121851. PubMed ID: 31812004
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of evobrutinib and its metabolite evobrutinib-diol in dog plasma by liquid chromatography combined with electrospray ionization tandem mass spectrometry.
Yang J; Yu H; Tang Q
Biomed Chromatogr; 2019 Sep; 33(9):e4575. PubMed ID: 31069837
[TBL] [Abstract][Full Text] [Related]
16. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.
Wu J; Sanai N; Bao X; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetic profiles of selected irreversible tyrosine kinase inhibitors, neratinib and pelitinib, with apigenin in rat plasma by UPLC-MS/MS.
Maher HM; Alzoman NZ; Shehata SM; Abahussain AO
J Pharm Biomed Anal; 2017 Apr; 137():258-267. PubMed ID: 28167419
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of tivantinib in rat plasma using ultra performance liquid chromatography with tandem mass spectrometry.
Bai YL; Yuan HC; Zhang DT; Liu Y; Zhang Y
J Pharm Biomed Anal; 2016 Jul; 126():98-102. PubMed ID: 27179187
[TBL] [Abstract][Full Text] [Related]
19. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Rood JJM; van Hoppe S; Schinkel AH; Schellens JHM; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2016 Jan; 118():123-131. PubMed ID: 26540627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
